Today, we take a look at a small developmental concern that recently saw its first insider buying in over two years after a recent decline.
The company has an early stage pipeline with multiple 'shots on goal' including a potentially more effective treatment for chronic anemia to decrease the frequency of blood transfusions.
A full investment analysis is presented in the paragraphs below.
A bureaucrat who said no to everything rarely got in trouble." - Tom Clancy, Executive Orders
Today, we take a look at a small 'Tier 4' biotech concern that saw several insiders